HOOKIPA Announces Executive Leadership Change
13 9월 2023 - 9:45PM
HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing
a new class of immunotherapeutics based on its proprietary
arenavirus platform, today announced that Katia Schlienger, M.D.,
Ph.D., is stepping down from her position as Chief Medical Officer
(CMO) to pursue new opportunities, effective September 30. Malte
Peters, M.D., a current member of the Board of Directors of
HOOKIPA, will lead HOOKIPA’s clinical activities ad interim as
Senior Clinical Advisor until a CMO search is complete. During this
time, Dr. Peters will remain a member of the HOOKIPA Board of
Directors.
Dr. Peters is a seasoned executive with deep
experience in bringing new therapies to patients. He retired from
his role as Chief Research and Development Officer at MorphoSys in
2022. Prior, Dr. Peters was Global Head of Clinical Development of
the biopharmaceuticals business unit of Sandoz in Germany and spent
12 years in leadership positions at Novartis Oncology. He was
responsible for multiple development programs and clinical trials
at Novartis, contributing to the approval of 28 cancer therapies.
He is board certified in internal medicine and earned his medical
degree from Freie Universität in Berlin, with a postdoctoral
fellowship in Toronto.
“We welcome Malte to HOOKIPA as we remain laser
focused on executing against our clinical priorities: to prepare
for the randomized trial of HB-200 in combination with
pembrolizumab, to progress our HB-300 prostate cancer program, and
to advance our partnered programs in our collaborations with Roche
and Gilead,” said Joern Aldag, Chief Executive Officer. “I would
like to thank Katia for her many contributions to HOOKIPA,
especially guiding our clinical programs and bringing our lead
HB-200 program to a successful proof-of concept in Phase 2. We wish
her the very best in her future endeavors.”
About HOOKIPAHOOKIPA Pharma
Inc. (NASDAQ: HOOK) is a clinical-stage biopharmaceutical company
focused on developing novel immunotherapies, based on its
proprietary arenavirus platform, which are designed to mobilize and
amplify targeted T cells and thereby fight or prevent serious
disease. HOOKIPA’s replicating and non-replicating technologies are
engineered to induce robust and durable antigen-specific CD8+ T
cell responses and pathogen-neutralizing antibodies. HOOKIPA’s
pipeline includes its wholly owned investigational arenaviral
immunotherapies targeting Human Papillomavirus 16-positive cancers,
prostate cancers, and other undisclosed programs. HOOKIPA is
collaborating with Roche on an arenaviral immunotherapeutic for
KRAS-mutated cancers. In addition, HOOKIPA aims to develop
functional cures of HBV and HIV in collaboration with Gilead.
Find out more about HOOKIPA online
at www.hookipapharma.com.
Forward Looking Statements
Certain statements set forth in this press
release constitute “forward-looking” statements within the meaning
of the Private Securities Litigation Reform Act of 1995, as
amended. Forward-looking statements can be identified by terms such
as “believes,” “expects,” “plans,” “potential,” “would” or similar
expressions and the negative of those terms. Such forward-looking
statements involve substantial risks and uncertainties that could
cause HOOKIPA’s research and clinical development programs, future
results, performance or achievements to differ significantly from
those expressed or implied by the forward-looking statements. Such
risks and uncertainties include, among others, the uncertainties
inherent in the drug development process, including HOOKIPA’s
programs’ early stage of development, the process of designing and
conducting preclinical and clinical trials, the regulatory approval
processes, the timing of regulatory filings, the challenges
associated with manufacturing drug products, HOOKIPA’s ability to
successfully establish, protect and defend its intellectual
property, risks relating to business
interruptions resulting from public health crises, the impact of
public health crises on the enrollment of patients and timing of
clinical results, and other matters that could affect the
sufficiency of existing cash to fund operations. HOOKIPA
undertakes no obligation to update or revise any forward-looking
statements. For a further description of the risks and
uncertainties that could cause actual results to differ from those
expressed in these forward-looking statements, as well as risks
relating to the business of the company in general, see HOOKIPA’s
quarterly report on Form 10-Q for the quarter ended
June 30, 2023, which is available on the SEC’s website
at www.sec.gov and HOOKIPA’s website
at www.hookipapharma.com.
Investors and others should note that we
announce material financial information to our investors using our
investor relations website (https://ir.hookipapharma.com/), SEC
filings, press releases, public conference calls and webcasts. We
use these channels, as well as social media, to communicate with
our members and the public about our company, our services and
other issues. It is possible that the information we post on social
media could be deemed to be material information. Therefore, we
encourage investors, the media, and others interested in our
company to review the information we post on the U.S. social media
channels listed on our investor relations website.
For further information, please contact:
Media |
Investors |
Instinctif Partners |
Reinhard Kandera, Chief Financial Officer |
hookipa@instinctif.com |
IR@hookipapharma.com |
+44 (0) 7457 2020 |
|
HOOKIPA Pharma (NASDAQ:HOOK)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
HOOKIPA Pharma (NASDAQ:HOOK)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024